Alyssa Michelle Bosso is a Frederick, Maryland based female rheumatologist who is specialized in Rheumatology. Active license number of Alyssa Michelle Bosso for Rheumatology is D0104194 in Maryland. Alyssa Michelle Bosso treat joint disease similar to orthopedists but do not perform surgeries. She diagnose and treat diseases of joints, muscle, bones and tendons which includes arthritis, back pain, muscle strains, common athletic injuries and 'collagen' diseases.
Complete Profile:
Alyssa Michelle Bosso speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Rheumatology
Credentials:
MD
Gender:
Female
Practice Address:
161 Thomas Johnson Dr Ste 250, Frederick, Maryland, 21702-4958
Phone:
301-942-7600
Fax:
301-694-0187
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1689202350
NPI Enumeration Date:
30 Mar, 2020
NPI Last Update On:
26 Jun, 2025
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Alyssa Michelle Bosso are as mentioned below.
License Number
Specialization
State
Status
D0104194
Rheumatologist
Maryland
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
7361 Calhoun Pl Ste 600, Rockville, Maryland
Zip:
20855-2788
Phone Number:
301-942-0442
Fax Number:
--
Patients can reach Alyssa Michelle Bosso at 161 Thomas Johnson Dr Ste 250, Frederick, Maryland or can call to book an appointment on 301-942-7600. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 14 July, 2025.